<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534647</url>
  </required_header>
  <id_info>
    <org_study_id>GLADEL LUPUS</org_study_id>
    <nct_id>NCT04534647</nct_id>
  </id_info>
  <brief_title>Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort</brief_title>
  <official_title>Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liga Panamericana de Asociaciones de Reumatologia (PANLAR)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Liga Panamericana de Asociaciones de Reumatologia (PANLAR)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lupus nephritis (LN) is one of the main manifestationsin SLE patients, having an important&#xD;
      impact on morbidity and mortality. Renal biopsy is the &quot;gold standard&quot; for the diagnosis of&#xD;
      LN, however, it is an invasive technique, not free of complications,which is not recommended&#xD;
      to be performed serially as a follow-up tool for patients with LN. Searching for biomarkers&#xD;
      in SLE has been the subject of interesting research, although results have not always been&#xD;
      relevant. Multiple biomarkers have been studied in different locations (soluble markers in&#xD;
      blood, urine and biological fluids),of different nature(autoantibodies, genetic markers of&#xD;
      &quot;kidney damage&quot;) looking atdiagnostic and/orprognostic features. In recent years, several&#xD;
      biomarkers have been developed that seek to find an association with pathological patterns,&#xD;
      with pathogenic mechanisms and with a non-invasive diagnosis of different glomerulopathies,&#xD;
      allowing the identification of prognostic subgroups in each type of kidney disease, while&#xD;
      predicting response to treatment and/or recurrence. To date, double-stranded anti-DNA&#xD;
      antibodies (anti-dsDNA) and serum complement are the only non-invasive routine biomarkers for&#xD;
      monitoring renal activity in patients with LN. However, these markers are only the reflection&#xD;
      of the immune activity of the disease and they are not markers of renal damage or poor&#xD;
      prognosis. For all the above, the purpose of this study is, in a case-control study, to&#xD;
      evaluate simultaneously serum (ANA, anti-dsDNA, anti-C1q, anti-cardiolipin IgG and IgM,&#xD;
      anti-ß2GPI IgG and IgM, anti-phosphatidylserine/prothrombin antibodies, and anti-DFS70&#xD;
      antibodies) and urinary biomarkers, and the presence of anti-DFS70 antibodies, in a&#xD;
      multiethnic cohort of patients with SLE such as the cohort of GLADEL, and assess its possible&#xD;
      correlation with various socio-demographic, clinical and serological manifestations of the&#xD;
      disease.&#xD;
&#xD;
      In subgroup of patients, transcriptome studies will be performed using RNA from blood and&#xD;
      tissue to identify possible transcriptional signatures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between urinary biomarkers and NL</measure>
    <time_frame>Baseline to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of clinical features of patients</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of immunological characteristics of patients with NL</measure>
    <time_frame>Baseline to 60 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lupus Nephritis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>different serum and urine biomarkers</intervention_name>
    <description>urine exosomes and serum biomarkers</description>
    <other_name>Transcriptome studies</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Each center will include 25 patients with SLE divided into four groups, each with their&#xD;
        corresponding healthy control (ratio 1:1).&#xD;
&#xD;
        Group 1.Patients with SLE, without renal involvement (never), of any time of disease&#xD;
        duration. Total: 10 patients.&#xD;
&#xD;
        Group 2.Patients with SLE, with prevalent renal involvement (at any time of evolution),&#xD;
        currently inactive (*): Total: 5 patients.&#xD;
&#xD;
        Group 3.Patients with SLE,with prevalent renal involvement (atany time of evolution),&#xD;
        currently active (*). Total: 5 patients.&#xD;
&#xD;
        Group 4.Patients with SLE,with incident renal involvementof recent onset (maximum 3&#xD;
        months), without immunosuppressive treatment and with renal biopsy (mandatory criterion).&#xD;
        Total: 5 patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients with a diagnosis of SLE will be included. Patients should meet at&#xD;
             least one ofthe classification criteria: ACR 1982/1997 (1) and/or SLICC 2012 (2) to&#xD;
             determine the efficacy of calcineurin inhibitor-containing treatment regimens in LN&#xD;
             cohorts by ethnic groups.&#xD;
&#xD;
          -  Age ≥18 years old.&#xD;
&#xD;
          -  Patients and controls that volunteer toparticipate and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other systemic autoimmune diseases or overlap syndrome (rheumatoid&#xD;
             arthritis, systemic sclerosis, dermatomyositis, systemic vasculitis and others).&#xD;
&#xD;
          -  Patients who have urinary infection, pregnancy or have a history of hepatitis B, C or&#xD;
             HIV virus infection.&#xD;
&#xD;
          -  Those patients presenting with antiphospholipid syndrome (APS) associated with lupus&#xD;
             will not be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Antonela Vannucci, SC</last_name>
    <phone>+543414261402</phone>
    <email>antonela.vannucci@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosana Quintana, DM</last_name>
    <phone>+5493415851333</phone>
    <email>rosanaquintana@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bernardo Pons-Estel</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Vannucci, SC</last_name>
      <phone>+543414261402</phone>
      <email>antonela.vannucci@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rosana Quintana, MD</last_name>
      <phone>+5493415851333</phone>
      <email>rosanaquintana@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liga Panamericana de Asociaciones de Reumatologia (PANLAR)</investigator_affiliation>
    <investigator_full_name>Bernardo A Pons-Estel</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

